COL18A1 and hereditary angioedema: The most utilized on demand therapies for patients with HAE nC1-INH were intravenous pdC1-INH (59%) and icatibant (38%; Supplementary Table 1), and for patients with AE-UNK, they were also intravenous pdC1-INH (52%), and icatibant (48%; Supplementary Table 1).